

POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, November 7th

THEME 8: Clinical Trials and Health Economics

P3-1 MINIMIZING TRIAL COSTS BY ACCELERATING/IMPROVING ENROLLMENT/RETENTION IN AD TRIALS IN GLOBAL CLINICAL TRIALS FOR ALZHEIMER'S DISEASE

Debbie N Coté, RN, Clinical R&D Consultant, San Francisco, California US
Contributing Author of Chapter 12: Minimizing trial costs by Accelerating/Improving Enrollment/Retention in AD trials In Global Clinical Trials for Alzheimer's Disease, 1st Edition Design, Implementation, and Standardization

P3-2 APPRAISAL OF THE UTILITY OF THE AMYLOID IMAGING TASKFORCE RECOMMENDATIONS FOR AMYLOID-PET PRESCRIPTION

Boccardi Marina, PhD (1), Altomare Daniele, MS (1), Guerra Ugo Paolo, MD (2), Pievani Michela, PhD (1), Albanese Emiliano, MD (3), Festari Cristina, MS (1), Antelmi Luigi, MS (1), Pasqualetti Patrizio, MS (4), Muscio Cristina, MS (1,5), Nobili Flavio, MD (6), Padovani Alessandro, MD (7), Frisoni Giovanni Battista, MD (1,8), & the INDIA-FBP Working Group*
(1) *Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy;* (2) *Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy;* (3) *Department of Mental Health and Psychiatry, University Hospital of Geneva, Geneva, Switzerland;* (4) *Fatebenefratelli Hospital of Isola Tiberina, Roma, Italy;* (5) *European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini of Gazzaniga, Bergamo, Italy;* (6) *Clinical Neurology, Department of Neuroscience (DINOEMI), University of Genoa, Genoa, Italy;* (7) *Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy;* (8) *Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland*

*Full list of INDIA-FBP participants:

http://www.centroalzheimer.org/sito/contenuti/ip_lilly_publications/INDIA-FBP_WORKING_GROUP.pdf

Project link: http://www.centroalzheimer.org/sito/ip_lilly.php

P3-3 ASSESSING THE FINANCIAL BURDEN ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT

Thanh G.N. Ton, PhD, MPH (1), Thomas DeLeire, PhD (2), Suepattra G. May, PhD, MPH (1), Ningqi Hou, MHS, PhD (1), Jennifer Benner, BA (1), Er Chen, PhD (3), Joshua Chodosh, MD (4)

(1) *Precision Health Economics, Los Angeles, CA, USA;* (2) *McCourt School of Public Policy, Georgetown University, Washington, DC, USA;* (3) *Genentech, Inc., San Francisco, CA, USA;* (4) *Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA*

P3-4 MULTICULTURAL DIFFERENCES TOWARD ALZHEIMER'S EDUCATION AND CLINICAL TRIAL PARTICIPATION ON ALZHEIMER'S UNIVERSE (WWW.ALZU.ORG)

Vanessa Cooper BS (1), Candace L Haddock MD (2), Jaclyn L. Chen BS (3), Max Pensack BS (3), Ciara Gaglio BA (3), Alon Seifan MD MS (3), Richard S. Isaacson MD (3)

(1) *New York Medical College, New York, NY, USA;* (2) *Mayo Clinic, Rochester, MN, USA* (3) *Weill Cornell Medical College, New York, NY, USA*

P3-5 USING SOCIAL MEDIA TO EDUCATE ABOUT CLINICAL TRIALS ON ALZHEIMER'S PREVENTION & TREATMENT VIA ALZHEIMER'S UNIVERSE (WWW.ALZU.ORG)

Candace L. Haddock, MD.(1) Ciara Gaglio, BA, (2) Jaclyn L. Chen BS,(2) Max Pensack BS (2), Alon Seifan, MD, MS, (2) Richard S. Isaacson, MD, (2)

(1) *Mayo Clinic, Rochester, MN, USA;* (2) *Weill Cornell Medical College, New York, NY, USA*

P3-6 MINIMIZING TRIAL COSTS BY ACCELERATING/IMPROVING ENROLLMENT/RETENTION IN AD TRIALS

Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization

Edited by Menghis Bairu, M.D., Michael Weiner, M.D.

Chapter 12: Minimizing Trial Costs by Accelerating/Improving Enrollment/Retention in AD Trials Debbie N Coté Cote, RN

THEME 9: Clinical Trials: Epidemiology and miscellaneous

P3-7 MODIFIABLE RISK FACTORS FOR DEMENTIA: A STRATEGY TO COUNTERACT THE POOR PROSPECTS?

Jesper Skov Neergaard, MSc (1), Katrine Dragsbæk, MSc (1), Henrik Bo Hansen, MSc(1), Kim Henriksen, PhD(1), Claus Christiansen, MD, DMSc (1), Morten Asser Karsdal, PhD (1)

(1) *Nordic Bioscience A/S, Herlev, Denmark*

P3-8 GENETIC EPIDEMIOLOGY OF ALZHEIMER'S DISEASE: GWAS SIGNIFICANT RISK FACTORS IN CHROMOSOME 19 AND THE APOE LOCUS CURSE

Sonia Moreno-Grau M.Sc.(1) , Isabel Hernández M.D. PhD. (1), Stefanie Heilmann Ph.D. (2,3), Susana Ruiz M.Sc.(1), Maitée Rosende-Roca M.D. (1), Ana Mauleón M.D. (1), Liliana Vargas M.D. (1), Octavio Rodríguez-Gómez M.D. (1), Montserrat Alegret Ph.D (1), Ana Espinosa M.Sc.(1), Gemma Ortega Ph.D. (1), Marina Tarragona M.Sc. (1), Carla Abdelnour M.D. (1), Domingo Sánchez M.D.(1), Wolfgang Maier M.D.(4,5), Oscar Sotolongo-Grau Ph.D.(1), Lluís Tàrraga M.Sc.(1), Alfredo Ramírez M.D. (2,4), Jesús López-Arrieta M.D.(6), Carmen Antúnez M.D.(7), Manuel Serrano-Ríos (8), Mercè Boada M.D. Ph.D. (1), & Agustín Ruiz M.D. Ph.D.(1)

(1) *Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.* (2) *Institute of Human Genetics, University of Bonn, Bonn, Germany.* (3) *Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany.* (4) *Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.* (5) *German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.* (6) *Memory Unit, University Hospital La Paz-Cantoblanco, Madrid, Spain.* (7) *Dementia Unit, University Hospital Virgen de la Arrixaca, Murcia, Spain.* (8) *Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) Spain, Hospital Clínico San Carlos, Madrid, Spain*

POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, November 7th

- P3-9 APOE GENOTYPE MODIFIES THE RELATIONSHIP BETWEEN VASCULAR RISK FACTORS AND COGNITIVE DECLINE**
Juarez-Cedillo Teresa, PhD (1), Rosas-Carrasco Oscar, MsC.(2) Gutiérrez- Gutiérrez Lidia A., MsC.(3)
(1) Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI. México D.F., (2) Instituto Nacional de Geriátria, SSA, México, (3) Instituto Nacional de la Nutrición Salvador Subirán. SSA. México
-
- P3-10 CLINICAL-PATHOLOGICAL CORRELATION IN A DEMENTIA UNIT IN BARCELONA**
Isabel Hernández, MD. PhD (1), Ana Mauleon , MD (1), Maiteé Rosende ,MD (1), Liliana Vargas, MD (1), Montse Alegret, PhD (1), Ana Espinosa, MSc (1), Gemma Cuberas, PhD (1), Pilar Cañabate , PhD (1), Mariola Moreno, SW (1), Ellen Gelpí , MD (2) PhD, M^a Jesús Rey, MD (2), Lluís Tarraga, MSc (1), Merce Boada , MD.PhD (1)
(1) Fundació ACE. (ICNA). Barcelona, (2) IDIBAPS. Banc de Teixits Neurològics de Catalunya
-
- P3-11 RESTING-STATE CARDIAC WORKLOAD IS RELATED TO BOTH INCREASED NEOCORTICAL AGGREGATION OF β -AMYLOID PROTEIN AND RELATIVE IMPAIRMENTS IN SPATIAL WORKING MEMORY IN PRE-CLINICAL ALZHEIMER'S DISEASE**
Claudia Y. Santos (1), Yen Ying Lim (2,3), Wen-Chih Wu (4), Shahena Polynice (5), Paul Maruff (3,6), Peter J. Snyder (1,2)
(1) Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA; (2) Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; (3) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; (4) Division of Cardiology, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA; (5) Department of Neuroscience, Brown University, Providence, RI, USA; (6) Cogstate Ltd., Melbourne, Victoria, Australia
-
- P3-12 BURDEN OF ALZHEIMER'S DISEASE: CLINICAL COMORBIDITIES AND CO-MEDICATIONS**
Nawal Bent-Ennakhil, MS (1), Lin Xie, MA, MS (2), Myrlene Sanon, MPH (3), Florence Coste, MS (1), Yuexi Wang, ME (2), M. Furaha Kariburyo, MPH (2), Peter Neumann, ScD (4), Howard Fillit, MD (5,6)
(1) Global Epidemiology, Lundbeck SAS, Issy-Les-Moulineaux, France; (2) StatinMed Research, Ann Arbor, MI, USA; (3) Health Economics and Outcomes Research, Otsuka America Pharmaceuticals, Princeton, NJ, USA; (4) Tufts-New England Medical Center, Boston, Massachusetts, USA; (5) Mount Sinai Medical Center, New York City, USA; (6) Alzheimer's Drug Discovery Foundation, New York, NY, USA
-
- P3-13 AN UPDATE ON ALZHEIMER'S DISEASE PATIENT & TREATMENT CHARACTERISTICS IN THE UNITED STATES**
Myrlene Sanon, MPH (1), Lin Xie, MS, MA, (2) Nawal Bent-Ennakhil, MS, (3) Florence Coste, MS,(3) Yuexi Wang, ME (2), M. Furaha Kariburyo, MPH (2), Peter Neumann, ScD, (4) Howard Fillit, MD (5,6)
(1) Health Economics and Outcomes Research, Otsuka America Pharmaceuticals, Princeton, NJ, USA; (2) StatinMed Research, Ann Arbor, MI, USA; (3) Global Epidemiology, Lundbeck SAS, Issy-Les-Moulineaux, France; (4) Tufts New England Medical Center, Boston, Massachusetts, USA; (5) Mount Sinai Medical Center, New York City, USA; (6) Alzheimer's Drug Discovery, New York, NY, USA
-
- P3-14 IDENTIFICATION OF A FAST PROGRESSION DEMENTIA PHENOTYPE: A COMPARATIVE EVALUATION OF TWO SHORT COGNITIVE SCREENING INSTRUMENTS**
Jesper Skov Neergaard, MSc (1), Katrine Dragsbæk, MSc (1), Henrik Bo Hansen, MSc (1), Kim Henriksen, PhD (1), Claus Christiansen, MD, DMSc (1), Morten Asser Karsdal, PhD (1)
(1) Nordic Bioscience A/S, Herlev, Denmark
-
- P3-15 GENETIC VALIDATION OF DRUG TARGETS FOR SECONDARY PREVENTION OF ALZHEIMER'S DISEASE**
Agustín Ruiz M.D. (1), André Lacour Ph.D.(2), Ana Espinosa M.Sc.(1), 5 Eva Louwersheimer M.D (3), Stefanie Heilmann Ph.D.(4,5), Isabel Hernández M.D. PhD. (1), Steffen Wolfgruber Dipl.-Psych.(2,6) ,Victoria Fernández Ph.D. (1), Holger Wagner M.Sc. (6), Maitée Rosende-Roca M.D. (1), Ana Mauleón M.D. (1), Sonia Moreno-Grau M.Sc. (1), Liliana Vargas M.D. (1), Yolande AL Pijnenburg M.D. Ph.D. (3), Ted Koene Ph.D. (3), Octavio Rodríguez-Gómez M.D. (1), Gemma Ortega Ph.D. (1), Susana Ruiz M.Sc. (1), Henne Holstege Ph.D (7), Oscar Sotolongo-Grau Ph.D. (1), Johannes Kornhuber M.D. (8), Oliver Peters M.D. (9), Lutz Frölich M.D. Ph.D. (10), Michael Hüll M.D.(11), Eckart Rütger M.D. (12), Jens Wiltfang M.D. PhD. (12), Martin Scherer M.D.(13), Steffi Riedel-Heller M.D. M.P.H.(16), Montserrat Alegret Ph.D. (1), Markus M Nöthen M.D. Ph.D. (4,5), Philip Scheltens M.D. Ph.D. (3), Michael Wagner Ph.D. (2,6), Lluís Tarraga M.Sc. (1), Frank Jessen M.D.(2,6,14), Mercè Boada M.D. Ph.D.(1), Wolfgang Maier M.D.(2,6), Wiesje M van der Flier M.D. Ph.D. (3,15) Tim Becker Ph.D. (2,17), Alfredo Ramirez M.D. (4,6)
(1) Research Center and Memory Clinic of Fundació ACE, Barcelona, Spain; (2) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; (3) VU University Medical Centre, Amsterdam, The Netherlands; (4) University of Bonn, Bonn, Germany; (5) University of Bonn, Bonn, Germany; (6) University of Bonn, Bonn, Germany; (7) VU University Medical Centre, Amsterdam, The Netherlands; (8) Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany; (9) Charité University Medicine, Berlin, Germany; (10) University of Heidelberg, Mannheim, Germany; (11) University of Freiburg, Freiburg, Germany; (12) University of Göttingen, Göttingen, Germany; (13) Medical Centre Hamburg- Eppendorf, Hamburg, Germany; (14) University of Cologne, Cologne, Germany; (15) VU University Medical Center, Amsterdam, The Netherlands; (16) University of Leipzig, Leipzig, Germany; (17) University of Bonn, Bonn, Germany
-
- P3-16 REPRESENTATIVENESS OF CLINICAL TRIAL POPULATIONS IN MILD AD DEMENTIA – A COMPARISON OF 18 MONTH OUTCOMES WITH REAL WORLD DATA FROM THE GERAS OBSERVATIONAL STUDY**
Annabel Barrett (1), Mark Belger (1), Grazia Dell'Agnello (2), Kristin K Wroblewski (3), Sethuraman Gopalan (3), David Henley (3), Joel Raskin (3), Catherine Reed (1)
(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly Italia, Sesto Fiorentino, Italy; (3) Eli Lilly and Company, Indianapolis, US

POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, November 7th

P3-17 THE DEMENTIA OF ALZHEIMER'S DISEASE MAY BE DUE TO A DECLINE IN THE MONOSACCHARIDE TRANSFERASE, ALG7, THAT IS INVOLVED IN THE N-GLYCOSYLATION PATHWAY

Jordan L. Holtzman, M.D., Ph.D.

University of Minnesota, Minneapolis, Minnesota, USA

P3-18 BUTYRYLCHOLINSTERASE K-VARIANT - A GENETIC MARKER OF POOR RESPONSE TO DONEPEZIL IN MILD COGNITIVE IMPAIRMENT.

Sophie Sokolow, RPh, PhD (1,2), X. Li, PhD (3,4), L. Chen, BSc (1), K. D. Taylor, PhD (3,4), J.I. Rotter, MD (3,4), R.A. Rissman, PhD (5,6), P.S. Aisen, MD (7), L. G. Apostolova, PhD (8)

(1) School of Nursing, University of California at Los Angeles, Los Angeles, CA, USA; (2) Brain Research Institute, University of California at Los Angeles, Los Angeles, CA, USA; (3) Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; (4) Division of Genomic Outcomes and Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; (5) Alzheimer's disease cooperative study, University of California San Diego, San Diego, CA, USA; (6) Department of Neuroscience, School of Medicine at UCSD, University of California San Diego, San Diego, CA, USA; (7) Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA; (8) Indiana University School of Medicine, Indiana Alzheimer's Disease Center, Indianapolis, IN, USA

P3-19 A NEW CLINICAL DIAGNOSTIC FRAMEWORK FOR ASSESSING PRECLINICAL ALZHEIMER'S DISEASE IN HEALTHY AT-RISK ADULTS: A WORK IN PROGRESS

Alon Seifan, MD, MS, (1) Robert Krikorian, PhD, (2) Max Pensack BS (1), Jaclyn L. Chen BS, (1) Josefina Meléndez-Cabrero, PhD, (3) Richard S. Isaacson, MD, (1)

(1) Weill Cornell Medical College, New York, NY, USA; (2) University of Cincinnati College of Medicine, Cincinnati, OH, USA; (3) Geropsychology Memory Clinic, San Juan, PR

THEME 10: Clinical Trials and Animal Models

P3-20 INTRANASAL DELIVERY OF STEM CELL FACTORS DECREASE ABETA AMYLOIDOSIS IN ANIMAL MODELS

Tristan Bolmont, PhD (1,2), Theo Lasser (1), Taoufiq Harach, Yuri Kudinov (3) MD, PhD, Alexei Lukashev, PhD (2)

(1) Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland; (2) Stemedica International, Epalinges, Switzerland; (3) Stemedica Cell Technologies, San Diego, CA, USA

P3-21 BI 409306, A NOVEL PHOSPHODIESTERASE 9A INHIBITOR, INCREASES CGMP IN CSF: RESULTS FROM NON-CLINICAL AND CLINICAL TRANSLATIONAL PROOF-OF-MECHANISM STUDIES

Holger Rosenbrock, PhD (1), Katja Boland, PhD (2), Viktoria Moschetti, MD (1), Holger Fuchs, PhD (1), Frank Runge, PhD (1), Michael Sand, MPH, PhD (3), Chantaratsamon Dansirikul, PhD (2), Solen Pichereau, PhD (2), Lien Gheyle, MD, PhD (4), Glen Wunderlich, PhD (5)

(1) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; (2) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; (3) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; (4) SGS Life Science Services – Clinical Research, Antwerpen, Belgium; (5) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada

P3-22 MICRORNA-574 IS INVOLVED IN COGNITIVE IMPAIRMENT IN 5-MONTH-OLD APP/PS1 MICE THROUGH REGULATION OF NEURITIN

Fei Li (1), Gang Wei (2), Ye Bai (1), Yunjun Li (1), Fengyuan Huang (1), Jian Lin (1), Qiuke Hou (1), Rudong Deng (1), Jian Hong Zhou (1), Sai Xia Zhang (1), Dong Feng Chen (1)

(1) Department of Anatomy, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China; (2) Research & Development of New Drugs, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China

P3-23 MODULATION OF THE IMPAIRMENT OF NEUROENDOCRINE-IMMUNE SYSTEM IN 3XTG-AD: EFFECTS OF POSTNATAL HANDLING AND NMDA-INDUCED STRESS

Lydia Giménez-Llort PhD (1), Raquel Baeta-Corral (1), Mónica De la Fuente MD.PhD (2)

(1) Institute of Neuroscience & Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Spain; (2) Department of Physiology (Animals Physiology II) Complutense University of Madrid, Spain

P3-24 ENRICHED ENVIRONMENT (EE): IMMEDIATE AND LONG TERM EFFECTS ON SPATIAL MEMORY

Edvaldo Soares, PhD

Sao Paulo State University, Laboratory of Cognitive Neuroscience-LaNeC, Marília, São Paulo, Brazil

P3-25 SUVN-502, A NOVEL 5-HT₆ RECEPTOR ANTAGONIST: PRECLINICAL EVIDENCE FOR THE DESIGN OF PHASE II STUDIES FOR ALZHEIMER'S DISEASE

Ramakrishna Nirogi, PhD, Pradeep Jayarajan, MS, Renny Abraham, MS, Gopinadh Bhyrapuneni, PhD, Vijay Benade, MS, Rajesh babu Medapatti, MS, Nageswararao Muddana, MS, Saivishal Daripelli, MS, Ramasastry Kambhampati, PhD.

Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

P3-26 MODULATION OF THE IMPAIRMENT OF NEUROENDOCRINE-IMMUNE SYSTEM IN 3XTG-AD: EFFECTS OF POSTNATAL HANDLING AND NMDA-INDUCED STRESS

Lydia Giménez-Llort PhD (1) Raquel Baeta-Corral (1), Mónica De la Fuente MD.PhD (2)

(1) Institute of Neuroscience & Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Spain; (2) Department of Physiology (Animals Physiology II) Complutense University of Madrid, Spain